The safety of long-acting β2-agonists in the treatment of stable chronic obstructive pulmonary disease

• Inhaled long-acting bronchodilators are the mainstay of pharmacotherapy for chronic obstructive pulmonary disease (COPD). Both the twice-daily long-acting β(2)-adrenoceptor agonists (LABAs) salmeterol and formoterol and the once-daily LABA indacaterol are indicated for use in COPD. This review examines current evidence for the safety of LABAs in COPD, focusing on their effect on exacerbations and deaths.

Subject headings

MEDICIN OCH HÄLSOVETENSKAP  -- Klinisk medicin -- Lungmedicin och allergi (hsv//swe)

MEDICAL AND HEALTH SCIENCES  -- Clinical Medicine -- Respiratory Medicine and Allergy (hsv//eng)

Keyword

Adrenergic beta-2 Receptor Agonists

adverse effects

Albuterol

adverse effects

analogs & derivatives

Blood Glucose

analysis

Cough

chemically induced

Ethanolamines

adverse effects

Headache

chemically induced

Humans

Indans

adverse effects

Nasopharyngitis

chemically induced

Potassium

blood

Pulmonary Disease

Chronic Obstructive

drug therapy

Quinolones

adverse effects

Respiratory Tract Infections

chemically induced

Spasm

chemically induced

Tachycardia

chemically induced

Tremor

chemically induced

Publication and Content Type

ref (subject category)

art (subject category)